Workflow
Integer (ITGR)
icon
Search documents
Integer Holdings Q1 Earnings & Revenues Beat Estimates, Margins Expand
ZACKS· 2025-04-25 17:50
Integer Holdings Corporation (ITGR) delivered adjusted earnings per share (EPS) of $1.31 in the first quarter of 2025, which improved 14.9% year over year. The figure topped the Zacks Consensus Estimate by 3.2%.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.The adjustments include expenses related to the amortization of intangible assets and restructuring and restructuring-related charges, among others.GAAP loss per share for the quarter was 66 cents, against EPS of 59 cents in the p ...
Integer (ITGR) - 2025 Q1 - Earnings Call Presentation
2025-04-24 18:22
Integer Holdings Corporation First Quarter 2025 Earnings Conference Call April 24, 2025 Integer Holdings Corporation First Quarter 2025 Earnings Conference Call 9 a.m. Eastern Time, April 24, 2025 Management Attendees: Diron Smith Executive Vice President, Chief Financial Officer Sanjiv Arora Senior Vice President, Strategy, Business Development & Investor Relations ITGR: 1Q25 Earnings Conference Call | April 24, 2025 | Page 2 Joe Dziedzic President, Chief Executive Officer Payman Khales President and CEO E ...
Integer (ITGR) - 2025 Q1 - Earnings Call Transcript
2025-04-24 18:21
Integer Holdings Corporation (NYSE:ITGR) Q1 2025 Earnings Conference Call April 24, 2025 9:00 AM ET Company Participants Sanjiv Arora - SVP-Strategy, Business Development & IR Joseph Dziedzic - President & CEO Payman Khales - President & CEO Elect Diron Smith - EVP & CFO Conference Call Participants Brett Fishbin - KeyBanc Capital Markets Craig Bijou - Bank of America Richard Newitter - Truist Securities Nathan Treybeck - Wells Fargo Andrew Cooper - Raymond James Joanne Wuensch - Citi Suraj Kalia - Oppenhei ...
Integer (ITGR) - 2025 Q1 - Quarterly Results
2025-04-24 12:07
EXHIBIT 99.1 Integer Holdings Corporation Reports First Quarter 2025 Results ~ Strong start to the year with 1Q25 financial results ~ ~ Reiterating 2025 sales and adjusted operating income outlook; raising adjusted EPS outlook ~ "Integer started the year off strong with first quarter 2025 sales growing at 7% year-over-year as we continue to execute our strategy by launching new products and adding capabilities in targeted growth markets. Integer also delivered 14% adjusted operating income growth," said Jos ...
Integer Announces CEO Succession Plan
Newsfilter· 2025-04-24 12:01
Leadership Transition - Joseph Dziedzic will retire as President and CEO of Integer Holdings Corporation effective October 24, 2025, and will step down from the Board of Directors [1] - Payman Khales, currently the Chief Operating Officer, will assume the role of President and CEO and join the Board at that time [1] - To ensure a smooth transition, Dziedzic will serve as an advisor to the company until March 31, 2026 [1] Achievements and Strategy - Dziedzic's leadership over the past eight years has driven significant growth and value creation for Integer, focusing on high-growth markets and unmet patient needs [2] - Under Dziedzic, the company accelerated investments in differentiated technologies and implemented the Integer Production System to enhance manufacturing consistency [2] - Integer is currently achieving above-market organic sales growth with expanding margins, positioning the company for continued growth [2] Incoming CEO Profile - Payman Khales has been with Integer since 2018, initially as President of the Cardio & Vascular business, where he successfully doubled sales in seven years [3][5] - As COO, Khales has overseen both of Integer's business units and has been integral to the development and execution of the company's strategy [3][5] - Khales holds an Executive MBA from Indiana University's Kelley School of Business and a Bachelor of Science in Mechanical Engineering from École Polytechnique de Montréal [6] Company Overview - Integer Holdings Corporation is a leading medical device contract development and manufacturing organization, serving cardiac rhythm management, neuromodulation, and cardio and vascular markets [7] - The company is committed to enhancing patient lives through innovative, high-quality products and solutions, with brands including Greatbatch Medical and Lake Region Medical [7]
What Analyst Projections for Key Metrics Reveal About Integer (ITGR) Q1 Earnings
ZACKS· 2025-04-22 14:21
The upcoming report from Integer (ITGR) is expected to reveal quarterly earnings of $1.27 per share, indicating an increase of 11.4% compared to the year-ago period. Analysts forecast revenues of $431.84 million, representing an increase of 4.1% year over year.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 1.6% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Prior to a compan ...
Integer Holdings Corporation Issues Statement on Tariffs
Newsfilter· 2025-04-11 11:00
Core Viewpoint - Integer Holdings Corporation is addressing the impact of tariffs on its business, estimating a potential effect of $1 to $5 million on full year adjusted operating income due to recent trade policy developments [2][6]. Company Overview - Integer Holdings Corporation (NYSE:ITGR) is a leading contract development and manufacturing organization in the medical device sector, focusing on cardiac rhythm management, neuromodulation, and cardiovascular markets [4]. - The company is recognized as a strategic partner for medical device companies and OEMs, committed to enhancing patient lives through innovative and high-quality products [4]. Financial Impact - The estimated impact of tariffs on Integer's adjusted operating income incorporates both currently applicable tariffs and additional tariffs announced on April 2, which will take effect after a 90-day pause [2]. - The company plans to release its financial and operational results for the first quarter of 2025 on April 24, 2025 [3].
Integer Schedules First Quarter 2025 Earnings Release and Conference Call for April 24, 2025
GlobeNewswire News Room· 2025-03-27 12:00
PLANO, Texas, March 27, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR) announced today that it plans to release financial and operational results for first quarter 2025 at 7 a.m. Central Time (CT) / 8 a.m. Eastern Time (ET) on Thursday, April 24, 2025. Following the release, Integer management will host a webcast at 8 a.m. CT / 9 a.m. ET to discuss these results. Other forward-looking and material information may also be discussed during this call. Conference call details: Date: Thursday ...
Integer Holdings Corporation Enhances Capitalization Structure with the Closing of $1.0 Billion Convertible Senior Notes Offering
Newsfilter· 2025-03-19 01:30
Core Viewpoint - Integer Holdings Corporation has successfully closed a $1.0 billion offering of 1.875% convertible senior notes due 2030, which is expected to enhance its capital structure and reduce interest expenses, thereby positively impacting adjusted earnings for 2025 [1][2]. Financial Impact - The offering was upsized from an initial $750 million to $875 million due to strong investor demand, with an additional $125 million purchased by initial purchasers [1][2]. - The transaction is projected to lower interest expenses by approximately $12 million in 2025, based on current outstanding debt and interest rates [2]. - The estimated net proceeds from the offering will be $976.1 million after deducting discounts and expenses, which will be used for various financial obligations including repaying existing debt [2]. Strategic Objectives - The transaction creates revolver capacity, allowing the company to continue its tuck-in acquisition strategy while maintaining a targeted leverage range of 2.5 to 3.5 times adjusted EBITDA [2]. - The structure of the convertible notes and associated capped calls is designed to mitigate potential dilution for investors in the future [2][3]. Conversion Details - Upon conversion, the principal amount of the notes will be paid in cash, with an effective conversion price set at $189.44, representing a 60% premium over the company's common stock closing price of $118.40 on March 13, 2025 [3]. - The company has the option to minimize future dilution by delivering the value of any conversion obligation owed in cash or a combination of cash and shares [3]. Company Overview - Integer Holdings Corporation is a leading medical device contract development and manufacturing organization, serving various markets including cardiac rhythm management and neuromodulation [4]. - The company is committed to providing innovative, high-quality products and solutions to enhance patient lives globally [4].
Integer Holdings Corporation Enhances Capitalization Structure with the Closing of $1.0 Billion Convertible Senior Notes Offering
GlobeNewswire· 2025-03-19 01:30
Core Viewpoint - Integer Holdings Corporation has successfully closed a $1.0 billion offering of 1.875% convertible senior notes due 2030, which is expected to enhance its financial structure and reduce interest expenses, thereby positively impacting adjusted earnings for 2025 [1][2]. Financial Impact - The offering was upsized from an initial $750 million to $875 million due to strong investor demand, with an additional $125 million purchased by initial purchasers [1]. - The transaction is projected to lower interest expenses by approximately $12 million in 2025, contributing to adjusted earnings [2]. - The estimated net proceeds from the offering will be $976.1 million after deducting discounts and expenses, which will be used to pay for capped call transactions, exchange existing convertible notes, and repay outstanding borrowings [2]. Strategic Objectives - The transaction creates revolver capacity, allowing the company to continue its tuck-in acquisition strategy while maintaining a targeted leverage range of 2.5 to 3.5 times adjusted EBITDA [2]. - The structure of the convertible notes includes capped calls that mitigate potential dilution for investors upon conversion [2][3]. Company Overview - Integer Holdings Corporation is a leading medical device contract development and manufacturing organization, serving various markets including cardiac rhythm management and neuromodulation [4]. - The company is committed to providing innovative, high-quality products and solutions to enhance patient lives globally [4].